MedTrace Logo

Web-based vs In-person Personalized Feedback Intervention for Comorbid Substance Use and Disordered Gambling

NCT01529047 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 361

Last updated 2023-06-27

No results posted yet for this study

Summary

Rates of gambling and substance use behaviors are elevated among emerging adults (ages 18-24), and these behaviors are individually and jointly associated with a host of negative consequences. Evidence suggests there is significant overlap between these behaviors as well as comorbidity of associated mental disorders (i.e., pathological gambling and substance abuse/dependence). Prior research suggests that a brief in-person delivered personalized feedback intervention (PFI) may be an effective method of reducing these behaviors and their associated consequences among emerging adults. Thus, the purpose of this study is to determine the relative efficacy of an in-person delivered PFI versus a Web-based PFI in reducing gambling, alcohol and marijuana use behaviors and related-consequences in a sample of emerging adults, as well as explore potential moderators and mediators of intervention efficacy and the longevity of intervention effects (over a period of 18-months).

Conditions

  • Gambling
  • Alcohol Consumption
  • Cannabis

Interventions

BEHAVIORAL

Personalized Feedback Intervention

Printed or electronic form containing personalized information about health-relevant behaviors

Sponsors & Collaborators

Principal Investigators

  • Mary E Larimer, Ph.D. · University of Washington Dept of Psychiatry & Behavioral Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01529047 on ClinicalTrials.gov